Lexicon Pharmaceuticals Inc. (LXRX) on Fast Track to Commercial Business Launch
This stock has never touched $5 during the last 12 months, as the company has made major strides in the Biotechnology & Drugs field during this period. It is therefore an outstanding stock investment opportunity. There are two strong business strategy planks on which investors can count for the road ahead. The management has chosen the strategic collaboration route for the business end of its breakthrough technology. This approach gives the company the freedom to integrate vertically on its own, or to use the marketing and distribution systems of its associates. The latter includes some of the most established players…